RHHBF News and Press, Roche Holding Ltd From 04/04/24

2024-04-04 13:11:10 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation Seeking A...

2024-03-31 09:25:35 ET Summary The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data ...

2024-03-22 09:30:41 ET Summary Tourmaline Bio, Inc.'s share price dropped by 37% after Chugai's Enspryng, an IL-6 blocker, failed to meet expectations in a study on myasthenia gravis. Tourmaline is developing TOUR006, its own IL-6 blocker, for thyroid eye disease and atherosclerot...

2024-03-21 07:00:09 ET More on Argenx SE argenx SE (ARGX) Q4 2023 Earnings Call Transcript argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion Argenx SE GAAP EPS of -$1.68 misses by $0.30, revenue of $374M beats by $10.28M ...

2024-03-20 06:14:16 ET Swiss contract drug manufacturer Lonza ( OTCPK:LZAGF ) ( OTCPK:LZAGY ) has agreed to acquire a large-scale biologics manufacturing site in California from Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) for $1.2B in cash.... Read the full article on Seekin...

2024-03-17 00:40:48 ET Summary Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is ...

2024-03-13 08:22:59 ET More on Poseida Therapeutics Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful Seeking Alpha’s Quant Rating on Poseida Therapeutics Historical earnings data for Poseida Therapeutics Financial informa...

2024-03-11 08:22:37 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-03-08 09:23:14 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio stock jumps 13% on positive data for DMD drug Regenxbio Q4 2023 Earnings Preview...

2024-03-05 09:57:44 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript Alnylam's Huge Opportunity Alnylam posts Q4 topline miss;...